The International Rare Diseases Research Consortium (IRDiRC) launched in April 2011 at the initiative of the European Commission and the National Institutes of Health (USA) to foster international collaboration in rare disease research.
The IRDiRC brings together researchers and organisations investing in rare disease research to achieve two main objectives: deliver 200 new therapies for rare diseases and the means to diagnose most rare diseases by the year 2020.
EURORDIS is actively involved in the IRDiRC Executive Committee, Scientific Committees and Working Groups. EURORDIS provides inputs and support to its IRDiRC representatives, contributing to key policy documents by submitting policy proposals and amendments that aim to ensure the presence of rare disease patients in the decision-making process of the IRDiRC.
